RESEARCH TRIANGLE PARK, N.C., Sept. 13 /PRNewswire/ — Max
Neeman International, a leading Indian CRO, announces the expansion
of therapeutic focused device clinical trial services in India. Max
Neeman has formed an experienced and world class team of medical
device experts specializing in carrying out cardiac device trials
– therapeutic, diagnostic and surgical. Coronary
artherectomy, cardiac stents, aneurysm, mitral valve regurgitation
and acute coronary syndrome form 90% of the total device trial
experience. These are multicentric global trials with patients as
high as 300. Along with prior experience of conducting device
trials, the specialized Max Neeman team and services adds an
enhanced level of company expertise in conducting simple to complex
device studies. Max Neeman also has medical device operations
and regulatory experience in various other device therapeutic areas
as well including CNS and Ophthalmology.
India is emerging as a destination of choice for medical device
development and conducting device trials as the market for
percutaneous coronary interventions has expanded. India’s
device market is currently valued at US $1.7 Billion and projected
to grow at the rate of 23% annually. Benefits which have
accelerated outsourcing of device trials to India include:
shortened product development cycle, faster time to market (by
approximately 30% due to faster patient recruitment) and testing
resulting in significant cost savings of about 40-50%. Max
Neeman International conducts device studies for small to large
device firms across the globe delivering high quality results at a
lower cost resulting in high client satisfaction.
About Max Neeman International
Max Neeman International is one of the leading and largest CROs in
India. Our specialty is that we offer services for the successful
conduct of Phase I-IV clinical and device trials for small and
mid-sized international and na
‘/>”/>
